Purpose
To evaluate in asymptomatic and symptomatic participants with PAD, the feasibility of recruitment and adherence, efficacy and
safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their
combinations
References
Chesney CM, et al & Elam MB: Niacin lowers fibrinogen in patients with peripheral artery disease (PAD). Circulation
1996, 94:#3419. (Not available online)
|
Farmacêutica